A phase I clinical trial led by researchers at University of California San Diego School of Medicine has demonstrated the long-term safety and feasibility of neural stem cell transplantation for ...
January 27, 2009 — Geron Corp announced it has received US Food and Drug Administration (FDA) approval for a phase 1 trial of GRNOPC1, a cell therapy derived from human embryonic stem cells (hESC), in ...
A phase 1 clinical trial demonstrated the long-term safety and feasibility of neural stem cell transplantation for treating chronic spinal cord injuries. The corresponding study was published in Cell ...
A Phase I clinical trial led by researchers at University of California San Diego School of Medicine has demonstrated the long-term safety and feasibility of neural stem cell transplantation for ...
A paradigm shift in the way we treat spinal injuries is now in sight, with the world's first regenerative cell therapy being granted approval for a registrational Phase I clinical trial. It's a ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological ...
Amyotrophic lateral sclerosis (ALS) is a fast-progressing neurodegenerative disease with an average survival time of three years and no effective treatments. In ALS, motor neurons in the spinal cord, ...
Stem cell therapy is a rapidly evolving and promising treatment for spinal-cord injuries. According to a new literature review, published in the April issue of the Journal of the American Academy of ...
Diagnosed with severe spina bifida, baby Nixon receives pioneering stem cell fetal surgery, gaining mobility beyond ...
Amyotrophic lateral sclerosis (ALS) is a fast-progressing neurodegenerative disease with an average survival time of three years and no effective treatments. In ALS, motor neurons in the spinal cord, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results